Abrocitinib bụ ọnụ, obere molecule, Janus kinase (JAK) 1 inhibitor na mmepe maka ọgwụgwọ nke ndị okenye na ndị nọ n'afọ iri na ụma nwere oke atopic dermatitis.

A na-enyocha Abrocitinib na nyocha ụlọ ọgwụ NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescent with Atopic Dermatitis).

Pfizer na-emepụta Abrocitinib ugbu a maka ọgwụgwọ atopic dermatitis (eczema). Ọ bụ onye na-egbochi Janus kinase 1 (JAK1) otu ugboro kwa ụbọchị nyocha.

Atopic dermatitis (AD) bụ mgbagwoju anya, nke na-adịghị ala ala, ọrịa akpụkpọ ahụ na-egbuke egbuke nke e ji itching, oké itching, na eczematous ọnya na-emetụta ihe dịka 25% ụmụaka na 2% ruo 3% nke ndị okenye n'ụwa nile. Abrocitinib bụ onye na-emechi ihe na-ahọrọ nke Janus kinase-1 (JAK1) enzyme na-egbochi usoro mkpali. Ya mere, anyị bu n'obi iji nyochaa nrụpụta na nchekwa nke abrocitinib maka AD dị oke-na-oke.

Abrocitinib na dose 100 mg ma ọ bụ 200 mg bụ ọgwụ dị irè, nke anabatara nke ọma na nke na-ekwe nkwa n'ịgwọ ndị ọrịa nwere oke atopic dermatitis. Otú ọ dị, nyocha ahụ kwadoro ịdị irè nke abrocitinib 200 mg karịa 100 mg, ma mmetụta ndị dị ka ọgbụgbọ na isi ọwụwa nwere ike ime karịa na 200 mg.